Video

Dr. Hurvitz on Sequencing Therapeutic Options in HER2+ Breast Cancer

Author(s):

Sara A. Hurvitz, MD, University of California, Los Angeles

In Partnership With:

Sara A. Hurvitz, MD, discusses sequencing therapeutic options for patients with HER2-positive breast cancer. 

Sara A. Hurvitz, MD, associate professor, David Geffen School of Medicine, University of California, Los Angeles (UCLA), medical oncologist, medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director, Santa Monica-UCLA Outpatient Oncology Practices, anddirector, Breast Cancer Clinical Trials Program, UCLA, discusses sequencing therapeutic options for patients with HER2-positive breast cancer. 

The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu) is a new standard-of-care approach in the second-line setting of HER2-positive breast cancer, Hurvitzsays. Trastuzumab deruxtecan improved patient outcomes compared with ado-trastuzumab emtansine (Kadcyla; T-DM1) and is utilized in patients who have progressed on trastuzumab (Herceptin) and taxane regimens, Hurvitz adds.

Moreover, the phase 2 HER2CLIMB (NCT02614794) trial demonstrated that tucatinib (Tukysa) plus capecitabine and trastuzumab showed activity in patients with brain metastases, Hurvitz emphasizes.

Ongoing efforts to expand HER2-targeted treatment options are ongoing, Hurvitz continues. Several novel HER2-targeted agents are currently in development, as well as additional targeted therapy combinations for this patient population, Hurvitz concludes.

Related Videos
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Marshall Posner, MD
Renee Saliby, MD, MSc
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Related Content
Lajos Pusztai, MD, DPhil
July 25th 2024

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Priscilla F. McAuliffe, MD, PhD, of UPMC Hillman Cancer Center
July 24th 2024

Novel Prompt Shows Potential to Decrease Overtreatment in Older Patients With Early-Stage Breast Cancer

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Paolo Tarantino, MD
July 23rd 2024

DESTINY-Breast03 and DESTINY-Breast06 Data Shape Metastatic Breast Cancer Treatment

Sonya Reid, MD, MPH
July 22nd 2024

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer